Summary
- The Indian Patent Office has refused AbbVie’s patent application for Mavyret, a key Hepatitis C treatment, after the company abandoned it.
- Despite initial hopes for generics to enter the market, experts warn that this refusal does not significantly change access dynamics due to existing patents and licensing agreements.
- The Medicines Patent Pool's agreement excludes India from selling generics, limiting potential benefits for public health programs like the National Viral Hepatitis Control Program.
- As patent challenges continue, the future of affordable Hepatitis C treatments in India remains uncertain, highlighting ongoing issues in pharmaceutical patent law.
Join the discussion — sign up to comment, upvote, and save articles.